Thame Laboratories has been named in advertisements(1) following breaches of the ABPI Code of Practice for the Pharmaceutical Industry, in addition it has been required to issue a corrective statement. The company has brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Thame Laboratories – Case AUTH/2971/8/17
For sending a letter to clinicians about Thamicarb Oral Solution (sodium bicarbonate) which was misleading and disparaged the professional opinions of the reader, Thame was ruled in breach of the following clauses of the Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.
Clause 3.2 - Promoting a medicine in a manner inconsistent with the details listed in its summary of product characteristics (SPC).
Clause 7.2 - Making misleading claims and implications.
Clause 7.4 - Making claims which could not be substantiated.
Clause 8.2 - Disparaging the professional opinion of a heath professional.
Clause 9.1 - Failing to maintain high standards.
Clause 9.5 - Referring to the Medicines and Healthcare products Regulatory Agency (MHRA) in promotional material without being specifically required to do so.
The Code of Practice Appeal Board required Thame Laboratories to issue a corrective statement to recipients of the letter at issue. This and the case report were published in the August Code of Practice Review and is available at www.pmcpa.org.uk.
1. The advertisements will appear in the British Medical Journal on 27 October, the Nursing Standard on 27 October and the Pharmaceutical Journal on 31 October.
Notes to editors: for more information contact Elly Button email@example.com 0207 7478884 or 07956437982.
The case report and public reprimand were published in the PMCPA August 2018 Code of Practice Review, and are available at http://www.pmcpa.org.uk/Pages/default.aspx